Tarsus Pharmaceuticals Reports 69% Revenue Growth to $173.9 Million in Q2 2026

Tarsus Pharmaceuticals, Inc. reported significant financial performance in its latest 10-Q filing for the second quarter of 2026, with total revenues reaching $173.9 million, a 69% increase from $102.7 million in the same period last year. The company attributed this growth primarily to robust product sales of its recently launched therapeutic, XDEMVY® (lotilaner ophthalmic solution), which generated $173.9 million in net sales. For the first half of 2026, total revenues amounted to $336.0 million, compared to $181.0 million in the first half of 2025, marking a year-over-year increase of 85%. Despite this revenue growth, Tarsus reported a net loss of $18.6 million for the quarter, slightly improved from a loss of $20.3 million in the prior year, and a net loss of $25.5 million for the first half of 2026, down from $45.5 million in the same period last year.

The company’s operating expenses also increased, totaling $193.8 million for the second quarter, up from $124.8 million in the previous year. This rise was driven by higher costs in research and development, which reached $31.0 million, and selling, general, and administrative expenses, which surged to $150.7 million. The increase in operating expenses reflects Tarsus's ongoing investment in commercial activities and product development, particularly for XDEMVY and its pipeline candidates. The company has also reported a significant increase in stock-based compensation expenses, which rose to $13.3 million for the quarter, compared to $8.2 million in the prior year.

In terms of operational developments, Tarsus has seen a doubling in the number of eye care professionals prescribing XDEMVY five or more times per week, indicating strong product adoption. The company has also engaged in direct-to-consumer marketing initiatives, which have reportedly increased website engagement by over 30%. Tarsus continues to expand its market presence, with plans to further develop its pipeline, including investigational products targeting ocular rosacea and Lyme disease prophylaxis.

Looking ahead, Tarsus has a positive outlook, bolstered by its recent strategic acquisitions, including iRenix Medical, Inc. and a planned acquisition of Alkeus Pharmaceuticals, Inc. These acquisitions are expected to enhance Tarsus's product offerings and market reach. The company has also entered into a private placement agreement expected to generate $125 million in gross proceeds, which will support its ongoing operations and development initiatives. As of June 30, 2026, Tarsus reported cash, cash equivalents, and marketable securities totaling $449.7 million, providing a solid financial foundation for its future growth plans.